Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Migration, Crosslink

📖

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

active

wiki page Created: 2026-04-02T07:19:51 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-disease-progression-time

📖 Wiki Page

mechanism1596 wordssynced 2026-04-02

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Overview

This synthesis provides a chronological mapping of disease progression across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). By aligning pathological events, biomarker changes, and clinical milestones, we can identify optimal therapeutic windows and biomarker screening opportunities.

This synthesis complements our [Disease Progression Staging Synthesis](/mechanisms/disease-progression-staging-synthesis), [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus), and [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis).

Conceptual Framework

Temporal Cascade Model

flowchart TD subgraph Preclinical A["Genetic Risk Factors"] --> B["Molecular Changes"] B --> C["Cellular Dysfunction"] C --> D["Subtle Biomarker Shifts"] end subgraph Prodromal D --> E["Early Clinical Symptoms"] E --> F["Biomarker Abnormalization"] end subgraph Clinical F --> G["Established Disease"] G --> H["Progressive Decline"] H --> I["Advanced Stage"] end style Preclinical fill:#0a1f0a,stroke:#2e7d32,color:#e0e0e0 style Prodromal fill:#3e2200,stroke:#ef6c00,color:#e0e0e0 style Clinical fill:#2d0f0f,stroke:#c62828,color:#e0e0e0

Alzheimer's Disease Timeline

Preclinical Phase (10-20 years before symptoms)

...

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Overview

This synthesis provides a chronological mapping of disease progression across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). By aligning pathological events, biomarker changes, and clinical milestones, we can identify optimal therapeutic windows and biomarker screening opportunities.

This synthesis complements our [Disease Progression Staging Synthesis](/mechanisms/disease-progression-staging-synthesis), [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus), and [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis).

Conceptual Framework

Temporal Cascade Model

Mermaid diagram (expand to render)

Alzheimer's Disease Timeline

Preclinical Phase (10-20 years before symptoms)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -20 to -15 years | Aβ plaque initiation | CSF Aβ42 ↓, PET + | Highest — prevention trials |
| -15 to -10 years | Synaptic dysfunction | FDG-PET ↓, fMRI changes | High — synaptic protection |
| -10 to -5 years | Tau pathology begins | CSF p-tau181 ↑, PET + | Moderate — anti-tau |
| -5 to -2 years | Neurodegeneration starts | MRI atrophy, NfL ↑ | Lower — neuroprotection |

Prodromal Phase (MCI)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -2 to 0 years | Memory complaints | CDR 0.5, MMSE 24-30 | Moderate — disease modification |
| 0 to +1 years | Objective memory impairment | CSF Aβ/tau, volumetric MRI | Lower — symptomatic + DMT |
| +1 to +2 years | Functional decline begins | ADL scales affected | Limited — combination therapy |

Clinical Phase (Dementia)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +2 to +5 years | Mild-moderate dementia | CDR 1-2, MMSE 12-24 | Limited — symptomatic care |
| +5 to +10 years | Severe dementia | CDR 3, MMSE <12 | Palliative focus |
| +10+ years | Advanced disease | Total care required | Palliative focus |

Parkinson's Disease Timeline

Preclinical Phase (5-20 years before motor symptoms)

Per Braak staging (2003) and recent evidence:

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -20 to -10 years | Enteric nervous system involvement | α-syn in GI tract, p-S129 + | Highest — α-syn clearance |
| -10 to -5 years | Peripheral autonomic dysfunction | RBD, constipation, smell loss | High — neuroprotection |
| -5 to -2 years | Brainstem involvement | DaTscan changes, REM sleep behavior disorder | Moderate — disease modification |
| -2 to -1 years | Substantia nigra vulnerability | Motor prodromal markers | Lower — dopaminergic therapy |

Prodromal Phase

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -1 to 0 years | Subtle motor signs | UPDRS I-II, smell test | Moderate — early intervention |
| 0 to +1 years | Clinical diagnosis | UK Brain Bank criteria | Lower — symptomatic therapy |
| +1 to +3 years | Motor fluctuations begin | Levodopa response, DaTscan | Limited — optimization |

Clinical Phase

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +7 years | Motor complications | UPDRS III, dyskinesias | Limited — device therapy |
| +7 to +10 years | Advanced disease | Cognitive decline, falls | Palliative focus |
| +10+ years | Severe disability | Nursing home care | Palliative focus |

ALS Timeline

Preclinical Phase (unknown duration, possibly years)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| Unknown | Genetic mutation carriage | C9orf72, SOD1, FUS | Highest — preventive trials |
| Unknown | Epigenetic changes | DNA methylation patterns | High — epigenetic therapy |
| Unknown | Metabolic alterations | Creatinine, weight | Moderate — metabolic support |

Prodromal Phase (months to 1-2 years)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -12 to -6 months | Fasciculations, cramps | CK elevation, neurophysiology | Moderate — early intervention |
| -6 to 0 months | Subtle weakness | ALSFRS-R 48, grip strength | Lower — neuroprotection |
| 0 to +3 months | Progressive weakness | ALSFRS-R decline rate | Limited — symptomatic |

Clinical Phase

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +12 months | Progressive weakness | ALSFRS-R monthly decline | Limited — disease modification |
| +12 to +24 months | Respiratory involvement | FVC decline, bulbar | Palliative focus |
| +24+ months | Advanced disease | BiPAP, feeding tube | Palliative focus |

Frontotemporal Dementia Timeline

Preclinical Phase (10-15 years)

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -15 to -10 years | GRN/C9orf72/MAPT mutation | Genetic carrier | Highest — prevention trials |
| -10 to -5 years | Early brain atrophy | MRI, FDG-PET | High — disease modification |
| -5 to -2 years | Subtle behavior changes | Neuropsych testing | Moderate — early intervention |

Prodromal Phase

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -2 to 0 years | Mild behavioral changes | FAB, CDR | Moderate — symptomatic |
| 0 to +1 years | FTD diagnosis | Clinical criteria | Lower — combination therapy |
| +1 to +3 years | Progressive deficits | ALSFRS-F, MRI | Limited |

Clinical Phase

| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +7 years | Severe impairment | Total care | Palliative focus |
| +7+ years | Advanced disease | Terminal | Palliative focus |

Cross-Disease Biomarker Temporal Comparison

Blood Biomarker Changes Timeline

| Biomarker | AD | PD | ALS | FTD |
|-----------|:--:|:--:|:---:|:---:|
| p-tau181/217 | -10 years ↑ | — | — | — |
| NfL | -5 years ↑ | -2 years ↑ | -6 months ↑ | -2 years ↑ |
| α-synuclein (seed) | — | -10 years + | — | — |
| TDP-43 | — | — | -1 year + | -2 years + |
| Neurogranin | -10 years ↑ | — | — | — |
| BDNF | ↓ | ↓ | ↓ | ↓ |

Imaging Biomarker Timeline

| Modality | AD | PD | ALS | FTD |
|----------|:--:|:--:|:---:|:---:|
| Amyloid PET | -20 years + | — | — | — |
| Tau PET | -10 years + | — | — | — |
| DaTscan | — | -5 years ↓ | — | — |
| FDG-PET | -10 years ↓ | -5 years ↓ | -1 year ↓ | -5 years ↓ |
| MRI atrophy | -5 years | -2 years | -6 months | -2 years |

Therapeutic Window Analysis

Optimal Intervention Windows by Disease

| Phase | AD Target | PD Target | ALS Target | FTD Target |
|-------|-----------|------------|------------|------------|
| Preclinical | Anti-Aβ vaccination | α-synuclein clearance | Gene silencing | GRN restoration |
| Prodromal | Tau oligomer inhibition | Neuroprotection | Neuroprotection | TDP-43 modulation |
| Early Clinical | Synaptic preservation | Dopamine optimization | Respiratory support | Behavior management |

Cross-Disease Therapeutic Priorities

| Disease | Preclinical Window | Prodromal Window | Early Clinical Window |
|---------|-------------------|------------------|----------------------|
| AD | -20 to -10 years | -5 to 0 years | 0 to +5 years |
| PD | -20 to -5 years | -5 to 0 years | 0 to +7 years |
| ALS | Unknown | -1 to 0 years | 0 to +2 years |
| FTD | -15 to -5 years | -5 to 0 years | 0 to +7 years |

Clinical Trial Design Implications

Enrichment Strategies by Phase

| Disease | Preclinical Trial | Prodromal Trial | Early Clinical Trial |
|---------|-------------------|-----------------|----------------------|
| AD | Aβ+ cognitively normal | MCI-Aβ+ | MCI-AD, mild AD |
| PD | RBD, smell loss, genetic | Prodromal PD | Early PD, motor + |
| ALS | Gene carriers | Pre-symptomatic | Definite ALS |
| FTD | Mutation carriers | bvFTD prodromal | FTD spectrum |

Endpoint Considerations

AD: CDR-SB, ADAS-Cog, PET amyloid/tau, CSF biomarkers
PD: MDS-UPDRS, DaTscan, α-syn seed amplification assay
ALS: ALSFRS-R, FVC, survival, NfL
FTD: FAB, CDR, MRI volumetric, NfL

Knowledge Gaps

Preclinical duration variability: Unknown why some progress rapidly, others slowly

Biomarker temporal ordering: Exact sequence of biomarker changes unclear

Genetic modifier effects: How genetic variants modify timelines

Therapeutic window validation: When exactly interventions become ineffective

Cross-disease similarities: Shared progression patterns not fully mapped

Population-specific timelines: Ethnic/racial differences in progression

References

[Braak et al. Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://doi.org/10.1007/s00401-002-0620-9)

[Jack et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)](https://doi.org/10.1016/S1474-4422(10)70043-0)

[Chio et al. Global epidemiology of ALS - a systematic review (2019)](https://doi.org/10.1080/21678421.2019.1587768)

[Beach et al. Lewy body disease staging system for PD (2018)](https://doi.org/10.1002/mds.27313)

[Chen et al. Blood biomarkers across neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00767-5)

[Preuss et al. ALS staging systems - clinical and biological correlates (2020)](https://doi.org/10.1002/amyot.2020.02.003)

[Hansson et al. Tau PET and amyloid PET in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Postuma et al. Prodromal PD criteria (2019)](https://pubmed.ncbi.nlm.nih.gov/31734979/)

[Miller et al. FTD clinical criteria and staging (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)

[Benatar et al. ALS prevention trials - challenges (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

📖 View canonical wiki page →

Related Entities

mechanisms-disease-progression-timeline-synthesis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-disease-progression-timeline-synthesis
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d98c87f82c37
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-disease-progression-timeline-synthesis'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

55

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Overview

Conceptual Framework

Temporal Cascade Model

Alzheimer's Disease Timeline

Preclinical Phase (10-20 years before symptoms)

Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping

Overview

Conceptual Framework

Temporal Cascade Model

Alzheimer's Disease Timeline

Preclinical Phase (10-20 years before symptoms)

Prodromal Phase (MCI)

Clinical Phase (Dementia)

Parkinson's Disease Timeline

Preclinical Phase (5-20 years before motor symptoms)

Prodromal Phase

Clinical Phase

ALS Timeline

Preclinical Phase (unknown duration, possibly years)

Prodromal Phase (months to 1-2 years)

Clinical Phase

Frontotemporal Dementia Timeline

Preclinical Phase (10-15 years)

Prodromal Phase

Clinical Phase

Cross-Disease Biomarker Temporal Comparison

Blood Biomarker Changes Timeline

Imaging Biomarker Timeline

Therapeutic Window Analysis

Optimal Intervention Windows by Disease

Cross-Disease Therapeutic Priorities

Clinical Trial Design Implications

Enrichment Strategies by Phase

Endpoint Considerations

Knowledge Gaps

References

💬 Discussion